Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset

Background: Mutations in GBA and LRRK2 genes have been implicated in Parkinson disease (PD), particularly in Ashkenazi Jews. Methods: An Israeli Ashkenazi cohort of 420 patients with PD, 333 elderly controls, and 3,805 young controls was screened for eight GBA mutations, which are associated with mild (N370S, R496H) and severe (84GG, IVS2 + 1, V394L, D409H, L444P, RecTL) Gaucher disease. Patients with PD and elderly controls were also genotyped for LRRK2 G2019S. Results: GBA carrier frequency was 17.9% in patients with PD compared to 4.2% in elderly and 6.35% in young controls. The proportion of severe mutation carriers among PD patient GBA carriers was 29% compared to 7% among young controls. Severe and mild GBA mutations increased the risk of developing PD by 13.6- and 2.2-fold, and affected the average age at PD onset (AAO), 55.7 and 57.9 years, compared to 60.7 years in patients without known GBA or LRRK2 mutations. Conclusions: These data demonstrate genotype-phenotype correlations between different GBA mutations and Parkinson disease (PD) risk and AAO in Ashkenazi Jews. Additionally, an earlier AAO was observed in LRRK2 G2019S carrier PD patients. Finally, these data demonstrate that a surprisingly high frequency, more than one third of our patient population, carried a mutation in GBA or LRRK2.

[1]  R. Carmi,et al.  Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population , 1998, Human mutation.

[2]  D Harrich,et al.  Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs , 1995, Journal of virology.

[3]  Kenji Nakashima,et al.  New consensus research on neuropathological aspects of familial amyotrophic lateral sclerosis with superoxide dismutase 1 (SOD1) gene mutations: Inclusions containing SOD1 in neurons and astrocytes , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[4]  Jean-Pierre Julien,et al.  Transgenic mouse models of amyotrophic lateral sclerosis. , 2006, Biochimica et biophysica acta.

[5]  Robert H. Brown,et al.  Molecular biology of amyotrophic lateral sclerosis: insights from genetics , 2006, Nature Reviews Neuroscience.

[6]  Catherine Lomen-Hoerth,et al.  The overlap of amyotrophic lateral sclerosis and frontotemporal dementia , 2002, Neurology.

[7]  Murray Grossman,et al.  TDP-43-Positive White Matter Pathology in Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions , 2007, Journal of neuropathology and experimental neurology.

[8]  D. Krasnewich,et al.  Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. , 2001, Molecular genetics and metabolism.

[9]  A. Dibernardo,et al.  Translating preclinical insights into effective human trials in ALS. , 2006, Biochimica et biophysica acta.

[10]  R. Nussbaum,et al.  Parkinsonism among Gaucher disease carriers , 2004, Journal of Medical Genetics.

[11]  D. Cleveland,et al.  ALS: A Disease of Motor Neurons and Their Nonneuronal Neighbors , 2006, Neuron.

[12]  Ichiro Nakashima,et al.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis , 2004, The Lancet.

[13]  K. Marder,et al.  Pilot association study of the β‐glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity , 2005, Movement disorders : official journal of the Movement Disorder Society.

[14]  Guy A Rouleau,et al.  Genetics of familial and sporadic amyotrophic lateral sclerosis. , 2006, Biochimica et biophysica acta.

[15]  D. Elstein,et al.  Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. , 2006, Blood cells, molecules & diseases.

[16]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[17]  N. Hattori,et al.  Dopaminergic neuronal dysfunction associated with parkinsonism in both a Gaucher disease patient and a carrier , 2007, Journal of the Neurological Sciences.

[18]  T. Nagatsu.  [Biochemistry of Parkinson's disease]. , 1988, Seikagaku. The Journal of Japanese Biochemical Society.

[19]  T. Dörk,et al.  Nuclear factor TDP‐43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping , 2001, The EMBO journal.

[20]  E. Sidransky,et al.  Gaucher Disease and the Synucleinopathies , 2006, Journal of biomedicine & biotechnology.

[21]  B. Giometto,et al.  Revised diagnostic criteria for neuromyelitis optica (NMO) , 2007, Journal of Neurology.

[22]  J. Powell,et al.  Familial amyotrophic lateral sclerosis , 1997, Neurology.

[23]  G. Carter,et al.  A4V superoxide dismutase mutation in apparently sporadic ALS resembling neuralgic amyotrophy , 2006, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[24]  E. Buratti,et al.  Nuclear factor TDP-43 binds to the polymorphic TG repeats in CFTR intron 8 and causes skipping of exon 9: a functional link with disease penetrance. , 2004, American journal of human genetics.

[25]  C. Bendotti,et al.  Lessons from models of SOD1-linked familial ALS. , 2004, Trends in molecular medicine.

[26]  J. Robertson,et al.  Neuronal intermediate filaments and ALS: a new look at an old question. , 2006, Biochimica et biophysica acta.

[27]  S. Pittock,et al.  Neuromyelitis optica IgG status in acute partial transverse myelitis. , 2006, Archives of neurology.

[28]  S. Olindo,et al.  Natural history of the visual impairment of relapsing neuromyelitis optica. , 2007, Ophthalmology.

[29]  John Q Trojanowski,et al.  Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs , 2004, Nature Medicine.

[30]  E. Sidransky.  Gaucher disease and parkinsonism. , 2005, Molecular genetics and metabolism.

[31]  A. Singleton,et al.  Glucocerebrosidase mutations are also found in subjects with early‐onset parkinsonism from Venezuela , 2006, Movement disorders : official journal of the Movement Disorder Society.

[32]  P. Shaw,et al.  Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. , 2006, Biochimica et biophysica acta.

[33]  S. Vukusic,et al.  Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis , 2006, Annals of neurology.

[34]  R. Hohlfeld,et al.  NMO-IgG in the diagnosis of neuromyelitis optica , 2007, Neurology.

[35]  Y. Matsumoto,et al.  Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination , 2007, Journal of the Neurological Sciences.

[36]  J. Slade,et al.  Amyotrophic Lateral Sclerosis Associated with Genetic Abnormalities in the Gene Encoding Cu/Zn Superoxide Dismutase: Molecular Pathology of Five New Cases, and Comparison with Previous Reports and 73 Sporadic Cases of ALS , 1998, Journal of neuropathology and experimental neurology.

[37]  M. Farrer,et al.  Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population , 2006, Neurology.

[38]  P. Kaplan,et al.  The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. , 2000, Archives of internal medicine.

[39]  A. Ludolph,et al.  Preclinical Trials – An Update on Translational Research in ALS , 2006, Neurodegenerative Diseases.

[40]  A. Kakita,et al.  TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation , 2007, Acta Neuropathologica.

[41]  M. Farrer.  Genetics of Parkinson disease: paradigm shifts and future prospects , 2006, Nature Reviews Genetics.

[42]  B. Miller,et al.  Are amyotrophic lateral sclerosis patients cognitively normal? , 2003, Neurology.

[43]  P. Grieb.  Transgenic models of amyotrophic lateral sclerosis. , 2004, Folia neuropathologica.

[44]  I. Mackenzie,et al.  Ubiquitin Immunohistochemistry Suggests Classic Motor Neuron Disease, Motor Neuron Disease With Dementia, and Frontotemporal Dementia of the Motor Neuron Disease Type Represent a Clinicopathologic Spectrum , 2005, Journal of neuropathology and experimental neurology.

[45]  P. Andersen,et al.  Clinicopathological phenotype of ALS with a novel G72C SOD1 gene mutation mimicking a myopathy , 2006, Muscle & nerve.

[46]  J. Aharon-Peretz,et al.  Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. , 2004, The New England journal of medicine.

[47]  Christine Klein,et al.  LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. , 2006, The New England journal of medicine.

[48]  Yi Zhao,et al.  Glucocerebrosidase mutations and risk of Parkinson disease in Chinese patients. , 2007, Archives of neurology.

[49]  Nir Giladi,et al.  Cross-Sectional Study of the Prevalence of Parkinson’s Disease in the Kibbutz Movement in Israel , 2001, Neuroepidemiology.

[50]  P C O'Brien,et al.  The clinical course of neuromyelitis optica (Devic’s syndrome) , 1999, Neurology.

[51]  A. Verkman,et al.  The Journal of Experimental Medicine CORRESPONDENCE , 2005 .

[52]  D. Neary,et al.  Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43 , 2007, Acta Neuropathologica.

[53]  E. Beutler,et al.  Hematologically important mutations: Gaucher disease. , 2005, Blood cells, molecules & diseases.

[54]  D. Elstein,et al.  The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. , 2005, The New England journal of medicine.

[55]  L. Skipper,et al.  Pathogenic mutations in Parkinson disease , 2007, Human mutation.

[56]  E. Sidransky,et al.  The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. , 2005, The New England journal of medicine.

[57]  A. Skotnicki,et al.  Parkinson's syndrome preceding clinical manifestation of Gaucher's disease , 1999, American journal of hematology.

[58]  T. Lesnick,et al.  The natural history of recurrent optic neuritis. , 2004, Archives of neurology.

[59]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[60]  William,et al.  The Metabolic and Molecular Bases of Inherited Disease (Scriver, C. R., Beaudet, A. L., Sly, W. S., Valle, D., Childs, B., Kinzler, K. W., and Vogelstein, B., eds., 8th ed., McGraw-Hill, New-York, 2001, 7012 p., $550.00) , 2004, Biochemistry (Moscow).

[61]  Bruce L. Miller,et al.  Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis , 2006, Science.

[62]  R. Mandler,et al.  Devic's neuromyelitis optica: A prospective study of seven patients treated with prednisone and azathioprine , 1998, Neurology.

[63]  E. Buratti,et al.  Depletion of TDP 43 overrides the need for exonic and intronic splicing enhancers in the human apoA-II gene , 2005, Nucleic acids research.

[64]  Hurng‐Yi Wang,et al.  Structural diversity and functional implications of the eukaryotic TDP gene family. , 2004, Genomics.

[65]  J. Lowe.  New pathological findings in amyotrophic lateral sclerosis , 1994, Journal of the Neurological Sciences.

[66]  J. Haines,et al.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.

[67]  K. Marder,et al.  Frequency of LRRK2 mutations in early- and late-onset Parkinson disease , 2006, Neurology.

[68]  D. Wingerchuk.  Diagnosis and Treatment of Neuromyelitis Optica , 2007, The neurologist.

[69]  Nir Giladi,et al.  The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease , 2007, Neurology.

[70]  M. Swash,et al.  Ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis. Morphology, distribution, and specificity. , 1991, Brain : a journal of neurology.

[71]  J. Aharon-Peretz,et al.  Gaucher disease associated with parkinsonism: Four further case reports , 2003, American journal of medical genetics. Part A.

[72]  Nir Giladi,et al.  Occurrence of Parkinson's syndrome in type I Gaucher disease. , 1996, QJM : monthly journal of the Association of Physicians.

[73]  T. Dawson,et al.  Molecular Pathways of Neurodegeneration in Parkinson's Disease , 2003, Science.

[74]  P. Vermersch,et al.  Immunosuppressive therapy is more effective than interferon in neuromyelitis optica , 2007, Multiple sclerosis.

[75]  H. Akiyama,et al.  TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. , 2006, Biochemical and biophysical research communications.

[76]  K. Ishii,et al.  Parkinsonism in type I Gaucher's disease. , 2006, Internal medicine.

[77]  P. S. St George-Hyslop,et al.  Analysis of the glucocerebrosidase gene in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[78]  E. Beutler,et al.  Hematologically important mutations , 2005 .

[79]  R. Schiffmann,et al.  Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? , 2003, Molecular genetics and metabolism.

[80]  E. Sidransky,et al.  Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. , 2007, Molecular genetics and metabolism.

[81]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[82]  E. Sidransky,et al.  Glucocerebrosidase mutations in subjects with parkinsonism. , 2004, Molecular genetics and metabolism.

[83]  B. Weinshenker,et al.  Revised diagnostic criteria for neuromyelitis optica , 2006, Neurology.

[84]  Yih-Ru Wu,et al.  Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese , 2007, Journal of Neurology, Neurosurgery & Psychiatry.

[85]  N. M. Reddy,et al.  Higher order arrangement of the eukaryotic nuclear bodies , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[86]  M. Farrer,et al.  [Genetics of Parkinson's disease]. , 2001 .